NEW YORK (GenomeWeb News) – Gen-Probe said this week that the US Food and Drug Administration has informed the firm that it has concluded that a panel review is no longer necessary for review of the firm's Progensa PCA3 assay. The firm had filed a Premarket Approval Application with the FDA in August 2010 and previously had been told that the test would have to be reviewed by the Immunology panel of the agency's Medical Devices Advisory Committee.